Welcome international healthcare professionals

This site is no longer supported and will not be updated with new content. You are welcome to browse and download all content already included in the site. Please note you will have to register your email address to access the site.

You are here

Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo

Soderquist R, Bates DJ, Danilov AV, Eastman A.

Leukemia. May 2013 [Epub ahead of print]

Chronic lymphocytic leukemia (CLL) is characterized by the deregulated accumulation and persistence of B lymphocytes in the blood. Although the exact causes of CLL are unknown, the evasion of apoptosis through the aberrant expression of B-cell lymphoma 2 (BCL2)-family proteins is a common feature. A class of compounds, termed Bcl-2 homology domain 3 (BH3) mimetics, has been developed to directly inhibit BCL2 proteins and selectively kill tumor cells.


E-Alert

Subscribe to our E-Alert to keep up to date with the new items in the Resource Centre


Search this site

Search form